*Applications will be reviewed on a rolling-basis, and this opportunity will remain open until a qualified candidate is identified.
A research opportunity is currently available in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
Our laboratory investigates non-replicating gene therapy vectors derived from adenoviruses. Adenovirus vectors are popular in clinical trials, with approximately one quarter of all gene therapy clinical trials using adenovirus vectors. In our lab, we study how adenoviruses interact with proteins in the blood and with receptors on cells, and we then study how these interactions affect the biodistribution and safety of adenovirus vectors in mouse models. Our goals are to understand the biology of adenovirus gene therapy vectors and to facilitate development of better vectors that can be targeted to specific organs.
Participants will receive training in vector design, vector manufacturing, protein-protein interactions and mouse models. The goals of this fellowship are to learn about adenovirus vector biology and to understand issues that affect the safety and efficacy of adenovirus gene therapy vectors.
Anticipated Appointment Start Date: As soon as a qualified candidate is identified; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2021-0040) in your email.